Symbols / STAB
STAB Chart
About
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company develops therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma, Inc. is based in Fort Collins, Colorado. Statera Biopharma, Inc. is a subsidiary of Biostax Corp.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 28.57K |
| Enterprise Value | 7.00M | Income | -91.83M | Sales | 3.69M |
| Book/sh | -0.20 | Cash/sh | 0.01 | Dividend Yield | — |
| Payout | 0.00% | Employees | 46 | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | 0.01 | P/B | -0.00 | P/C | — |
| EV/EBITDA | -0.34 | EV/Sales | 1.90 | Quick Ratio | 0.04 |
| Current Ratio | 0.06 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -9.44 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | 183.50% | Earnings | — | ROA | -23.85% |
| ROE | -286.94% | ROIC | — | Gross Margin | 70.27% |
| Oper. Margin | -230.65% | Profit Margin | 0.00% | Shs Outstand | 71.42M |
| Shs Float | 48.11M | Short Float | 1.65% | Short Ratio | 0.39 |
| Short Interest | — | 52W High | 0.01 | 52W Low | 0.00 |
| Beta | 220.70 | Avg Volume | 12.96K | Volume | 700.00 |
| Target Price | — | Recom | None | Prev Close | $0.00 |
| Price | $0.00 | Change | 300.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$0.09
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—
- Duluth police investigate stabbing - Duluth News Tribune Sun, 18 Jan 2026 08
- Intel Takes Another Stab at AI GPUs - The Motley Fool hu, 16 Oct 2025 07
- Bismarck man stabbed in Mandan - KFYR-TV Mon, 15 Dec 2025 08
- Orange County therapist fatally stabbed at office by former patient, deputies say - Orlando Sentinel ue, 20 Jan 2026 08
- BHP walks away from last stab at Anglo American takeover - Reuters Mon, 24 Nov 2025 08
- Maine lawmakers take another stab at bump stock ban - Spectrum News hu, 27 Mar 2025 07
- Buellton Woman Arrested for Attempted Murder After Allegedly Stabbing Boyfriend Several Times - The Santa Barbara Independent Mon, 31 Mar 2025 07
- What Is Going on With Statera (STAB) Stock Today? - InvestorPlace hu, 06 Oct 2022 07
- 'Miracle' that doctor wasn't killed after being stabbed during 'vicious' home invasion, court hears - BreakingNews.ie Mon, 26 Jan 2026 08
- Ritual Vision’s First Quarter: Sold-Out Stock, A Forthcoming Film, and Grom Hysteria - Stab Mag Wed, 19 Feb 2025 08
- PYPL: PayPal Holdings Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits Fri, 21 Aug 2015 13
- When MMT Meets The S&P - Forbes Wed, 17 Jun 2020 07
- HDFC Bank Sees Robust Trading Activity Amidst Market Stability - Markets Mojo Wed, 26 Nov 2025 08
- Statera Biopharma (STAB) Stock Price, News & Analysis $STAB - MarketBeat Mon, 13 Sep 2021 13
- Four people found stabbed in Hoke County home, deputies investigating - WRAL hu, 28 Aug 2025 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2021-12-31 |
|---|---|
| TaxEffectOfUnusualItems | 0.00 |
| TaxRateForCalcs | 0.00 |
| NormalizedEBITDA | 38.93M |
| TotalUnusualItems | -68.00M |
| TotalUnusualItemsExcludingGoodwill | -68.00M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -101.85M |
| ReconciledDepreciation | 255.57K |
| ReconciledCostOfRevenue | 488.31K |
| EBITDA | -29.06M |
| EBIT | -29.32M |
| NetInterestIncome | -4.56M |
| NormalizedIncome | -33.85M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -101.85M |
| TotalExpenses | 29.32M |
| TotalOperatingIncomeAsReported | -98.34M |
| DilutedAverageShares | 35.11M |
| BasicAverageShares | 35.11M |
| DilutedEPS | -2.90 |
| BasicEPS | -2.90 |
| DilutedNIAvailtoComStockholders | -101.85M |
| NetIncomeCommonStockholders | -101.85M |
| NetIncome | -101.85M |
| MinorityInterests | 24.35K |
| NetIncomeIncludingNoncontrollingInterests | -101.88M |
| NetIncomeDiscontinuousOperations | 1.00 |
| NetIncomeContinuousOperations | -101.88M |
| PretaxIncome | -101.88M |
| OtherIncomeExpense | -68.00M |
| SpecialIncomeCharges | -68.00M |
| OtherSpecialCharges | -1.03M |
| WriteOff | 67.60M |
| RestructuringAndMergernAcquisition | 1.43M |
| NetNonOperatingInterestIncomeExpense | -4.56M |
| TotalOtherFinanceCost | 4.56M |
| OperatingIncome | -29.32M |
| OperatingExpense | 28.83M |
| OtherOperatingExpenses | -1.49M |
| ResearchAndDevelopment | 11.83M |
| SellingGeneralAndAdministration | 18.49M |
| SellingAndMarketingExpense | 79.44K |
| GeneralAndAdministrativeExpense | 18.41M |
| OtherGandA | 5.82M |
| InsuranceAndClaims | 640.38K |
| SalariesAndWages | 11.95M |
| GrossProfit | -488.31K |
| CostOfRevenue | 488.31K |
| TotalRevenue | 0.00 |
| OperatingRevenue | 0.00 |
| Line Item | 2021-12-31 |
|---|---|
| OrdinarySharesNumber | 35.48M |
| ShareIssued | 35.48M |
| NetDebt | 13.36M |
| TotalDebt | 16.26M |
| TangibleBookValue | -12.42M |
| InvestedCapital | 13.63M |
| WorkingCapital | -7.09M |
| NetTangibleAssets | -12.42M |
| CapitalLeaseObligations | 1.06M |
| CommonStockEquity | -1.57M |
| TotalCapitalization | 9.06M |
| TotalEquityGrossMinorityInterest | -1.51M |
| MinorityInterest | 61.27K |
| StockholdersEquity | -1.57M |
| GainsLossesNotAffectingRetainedEarnings | -6.65K |
| RetainedEarnings | -129.48M |
| AdditionalPaidInCapital | 127.74M |
| CapitalStock | 177.42K |
| CommonStock | 177.42K |
| PreferredStock | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 22.68M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 11.43M |
| LongTermDebtAndCapitalLeaseObligation | 11.43M |
| LongTermCapitalLeaseObligation | 806.14K |
| LongTermDebt | 10.62M |
| CurrentLiabilities | 11.25M |
| OtherCurrentLiabilities | 325.89K |
| CurrentDeferredLiabilities | 373.47K |
| CurrentDeferredRevenue | 373.47K |
| CurrentDebtAndCapitalLeaseObligation | 4.83M |
| CurrentCapitalLeaseObligation | 255.00K |
| CurrentDebt | 4.58M |
| OtherCurrentBorrowings | 4.38M |
| CurrentNotesPayable | 200.00K |
| PayablesAndAccruedExpenses | 5.72M |
| CurrentAccruedExpenses | 1.75M |
| InterestPayable | 51.20K |
| Payables | 3.96M |
| AccountsPayable | 3.96M |
| TotalAssets | 21.17M |
| TotalNonCurrentAssets | 17.01M |
| OtherNonCurrentAssets | 5.00M |
| GoodwillAndOtherIntangibleAssets | 10.85M |
| OtherIntangibleAssets | 1.58M |
| Goodwill | 9.27M |
| NetPPE | 1.17M |
| AccumulatedDepreciation | -30.05K |
| GrossPPE | 1.20M |
| OtherProperties | 998.72K |
| MachineryFurnitureEquipment | 197.56K |
| CurrentAssets | 4.16M |
| OtherCurrentAssets | 20.04K |
| AssetsHeldForSaleCurrent | 8.12K |
| CurrentDeferredAssets | 611.74K |
| RestrictedCash | 172.00K |
| PrepaidAssets | 1.02M |
| Receivables | 348.75K |
| OtherReceivables | 132.57K |
| AccountsReceivable | 216.18K |
| CashCashEquivalentsAndShortTermInvestments | 1.98M |
| OtherShortTermInvestments | 134.60K |
| CashAndCashEquivalents | 1.84M |
| Line Item | 2021-12-31 |
|---|---|
| FreeCashFlow | -28.38M |
| RepaymentOfDebt | -897.74K |
| IssuanceOfDebt | 14.67M |
| IssuanceOfCapitalStock | 7.34M |
| CapitalExpenditure | -182.97K |
| InterestPaidSupplementalData | 1.25M |
| EndCashPosition | 6.84M |
| BeginningCashPosition | 593.87K |
| EffectOfExchangeRateChanges | -6.65K |
| ChangesInCash | 6.26M |
| FinancingCashFlow | 20.99M |
| CashFlowFromContinuingFinancingActivities | 20.99M |
| NetOtherFinancingCharges | -129.26K |
| NetPreferredStockIssuance | 0.00 |
| PreferredStockIssuance | 0.00 |
| NetCommonStockIssuance | 7.34M |
| CommonStockIssuance | 7.34M |
| NetIssuancePaymentsOfDebt | 13.77M |
| NetLongTermDebtIssuance | 13.77M |
| LongTermDebtPayments | -897.74K |
| LongTermDebtIssuance | 14.67M |
| InvestingCashFlow | 13.46M |
| CashFlowFromContinuingInvestingActivities | 13.46M |
| NetBusinessPurchaseAndSale | 13.65M |
| SaleOfBusiness | 13.65M |
| NetPPEPurchaseAndSale | -182.97K |
| PurchaseOfPPE | -182.97K |
| OperatingCashFlow | -28.19M |
| CashFlowFromContinuingOperatingActivities | -28.19M |
| ChangeInWorkingCapital | 1.07M |
| ChangeInOtherWorkingCapital | 242.64K |
| ChangeInOtherCurrentLiabilities | -92.72K |
| ChangeInOtherCurrentAssets | 991.29K |
| ChangeInPayablesAndAccruedExpense | 1.00M |
| ChangeInPrepaidAssets | -981.89K |
| ChangeInReceivables | -94.52K |
| ChangesInAccountReceivables | -352.09K |
| OtherNonCashItems | -1.30M |
| StockBasedCompensation | 6.06M |
| AssetImpairmentCharge | 67.60M |
| DepreciationAmortizationDepletion | 255.57K |
| DepreciationAndAmortization | 255.57K |
| AmortizationCashFlow | 233.12K |
| AmortizationOfIntangibles | 233.12K |
| Depreciation | 22.45K |
| NetIncomeFromContinuingOperations | -101.88M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for STAB
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|